| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| OYLER JOHN | Chief Executive Officer, Director | C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND | /s/ Qing Nian, as Attorney-in-Fact | 2025-09-18 | 0001042047 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ONC | American Depositary Shares | Sale | -$1.32M | -4.07K | -14.62% | $324.12 | 23.7K | Sep 16, 2025 | Direct | F6, F7, F8 |
| transaction | ONC | American Depositary Shares | Sale | -$2.24M | -6.88K | -29% | $325.06 | 16.9K | Sep 16, 2025 | Direct | F6, F7, F9 |
| transaction | ONC | American Depositary Shares | Sale | -$4.06M | -12.4K | -73.85% | $326.14 | 4.41K | Sep 16, 2025 | Direct | F6, F7, F10 |
| transaction | ONC | American Depositary Shares | Sale | -$1.31M | -4.01K | -90.93% | $326.90 | 400 | Sep 16, 2025 | Direct | F6, F7, F11 |
| transaction | ONC | American Depositary Shares | Sale | -$131K | -400 | -100% | $327.78 | 0 | Sep 16, 2025 | Direct | F6, F7 |
| holding | ONC | Ordinary Shares | 7.45M | Sep 16, 2025 | Direct | ||||||
| holding | ONC | Ordinary Shares | 482K | Sep 16, 2025 | See Footnote | F1 | |||||
| holding | ONC | Ordinary Shares | 7.72M | Sep 16, 2025 | See Footnote | F2 | |||||
| holding | ONC | Ordinary Shares | 28.2M | Sep 16, 2025 | See Footnote | F3 | |||||
| holding | ONC | Ordinary Shares | 9.55M | Sep 16, 2025 | See Footnote | F4 | |||||
| holding | ONC | Ordinary Shares | 102K | Sep 16, 2025 | See Footnote | F5 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. |
| F2 | These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| F3 | These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| F4 | These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. |
| F5 | These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership. |
| F6 | Each American Depositary Share represents 13 Ordinary Shares |
| F7 | The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2025. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.61 to $324.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.61 to $325.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.62 to $326.61, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| F11 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.62 to $327.20, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |